The Chinese Biopharmaceutical Association of New England Chapter (CBA-NE) is a non-profit organization established in 2021. It's the New England chapter of the broader Chinese Biopharmaceutical Association (CBA), which was founded in 1995.

CBA-NE is dedicated to helping members grow professionally and personally. It provides a platform for networking, mentoring, and collaboration through various events like seminars, workshops, and networking mixers. The association's activities often focus on emerging trends and technologies, including the application of advanced technologies like AI to accelerate scientific discovery and therapeutic development. By fostering connections between academic researchers and industry leaders, CBA-NE plays a vital role in driving innovation within the New England biopharmaceutical ecosystem.

CBA-NE Mission

To empower the next generation of biopharmaceutical leaders by serving as a bridge between academic innovation and industry application. We are committed to fostering a collaborative ecosystem that accelerates the integration of advanced technologies (particularly artificial intelligence (AI)), to drive breakthroughs in healthcare and life sciences.

Join Us

Leadership Team

Yali Li, PhD

Dr. Yali Li is Vice President of Biostatistics and Data Management at bioMérieux, with over 20 years of experience in biostatistics, data science, and translational research. She has led high-performing teams across biopharmaceutical and biotech companies including Function Oncology, Exact Sciences, and Foundation Medicine, driving innovation in precision medicine, cancer diagnostics, and evidence generation. Her leadership has contributed to FDA-approved companion diagnostics, multi-cancer early detection initiatives, and the integration of data science in therapeutic and diagnostic development.
Dr. Li holds a Ph.D. in Biostatistics and an M.S. in Molecular Biology and Microbiology from Case Western Reserve University. She is passionate about advancing precision medicine and improving public health through innovative applications of statistics and data science.
Hao Cai, PhD

Dr. Cai is a biotech BD&L executive with over 20 years of international experience in drug discovery, clinical development, external innovation, and cross-border licensing. He currently represents a China Pharmaceutical company based in the greater Boston area, where he has led high-value out-licensing transactions and strategic collaborations with U.S. partners.
With a medical background and training in China, the United Kingdom, and Switzerland, Dr. Cai combines scientific expertise with business insight. His career spans the entire drug development continuum, from preclinical research to clinical development and licensing deals, supported by extensive networks across the United States, Europe, and Asia.
Jian Guan, PhD

Dr. Guan is a seasoned leader with extensive expertise in early- and late-stage drug development, encompassing product lifecycle management, risk mitigation, and CMC-related studies. He has a strong track record in preparing regulatory documentation to support IND and BLA submissions for biotherapeutics, including mRNA, monoclonal antibodies (mAb), and recombinant protein drugs.
With over 15 years of experience across academia, biotechnology, and the biopharmaceutical industry in the U.S., Jian excels at building and guiding high-performing R&D and portfolio teams. He collaborates closely with cross-functional stakeholders to design and execute strategic initiatives that accelerate project delivery and optimize time-to-market.
Jian holds a Ph.D. in Physical Chemistry from Jilin University and is certified in Advanced Management at Babson College.